Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 10 of 18
Next
>>
>
226 to 250 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
BT-549	Trametinib	3	72	sigmoid	sigmoid	BT549 trametinib 0 3 72	8	1.755	Inf	0.553	0.223	0.107	0.505	0.899	0.942	0.000194	NA	Inf	0.642	0.817	0.104	0.595	0.804	0.938	0.000236	NA
HCC38	BX-912	1	72	sigmoid	sigmoid	HCC38 BX-912 0 1 72	8	1.760	0.529	-0.322	0.274	0.591	-0.322	4.49	0.999	1.36e-10	NA	0.584	0.149	0.818	0.541	0.149	4.63	0.999	8.39e-10	NA
BT-20	AS605240	2	72	sigmoid	sigmoid	BT20 AS-605240 0 2 72	8	1.846	4509270.0	0.729	0.203	320.0	0.31	0.101	0.845	0.00373	NA	4.4e+12	0.764	0.821	56.5	0.46	0.101	0.843	0.00388	NA
BT-549	Trametinib	2	72	sigmoid	sigmoid	BT549 trametinib 0 2 72	8	1.914	Inf	0.602	0.2	0.0685	0.581	0.837	0.995	1.05e-07	NA	Inf	0.654	0.822	0.0601	0.638	0.839	0.995	1.04e-07	NA
HCC1806	Trametinib	3	72	sigmoid	sigmoid	HCC1806 trametinib 0 3 72	8	3.204	Inf	0.822	0.12	0.00981	0.829	0.872	0.97	2.67e-05	NA	Inf	0.742	0.822	0.00864	0.752	0.892	0.97	2.67e-05	NA
HCC1806	Trametinib	2	72	sigmoid	sigmoid	HCC1806 trametinib 0 2 72	8	2.836	Inf	0.8	0.135	0.00973	0.808	0.873	0.97	2.67e-05	NA	Inf	0.742	0.822	0.00864	0.752	0.892	0.97	2.67e-05	NA
HCC1806	Trametinib	1	72	sigmoid	sigmoid	HCC1806 trametinib 0 1 72	8	2.751	Inf	0.795	0.139	0.00972	0.802	0.873	0.97	2.67e-05	NA	Inf	0.742	0.822	0.00864	0.752	0.892	0.97	2.67e-05	NA
HCC38	Buparlisib	3	72	sigmoid	sigmoid	HCC38 buparlisib 0 3 72	8	1.431	0.674	-0.377	0.272	1.67	-1.0	1.21	0.991	6.94e-07	NA	1.11	0.188	0.824	1.11	0.0	1.32	0.987	2.46e-06	NA
BT-20	Alpelisib	1	72	sigmoid	sigmoid	BT20 alpelisib 0 1 72	8	2.077	1.14	0.046	0.196	3.52	-1.0	0.977	0.966	4.1e-05	NA	1.32	0.26	0.825	1.32	0.0	1.13	0.942	0.000194	NA
BT-549	Trametinib	1	72	sigmoid	sigmoid	BT549 trametinib 0 1 72	8	1.812	Inf	0.596	0.202	0.131	0.523	0.61	0.959	6.65e-05	NA	28.3	0.664	0.828	3.47	0.254	0.337	0.933	0.000305	NA
Hs 578T	BX-912	2		sigmoid	sigmoid	Hs578T BX-912 2	8	2.540	1.07	-0.019	0.174	1.79	-0.489	1.33	0.998	6.37e-09	NA	1.01	0.164	0.828	1.01	0.0	1.4	0.996	7.64e-08	NA
HCC1806	GDC-0980	2	72	sigmoid	sigmoid	HCC1806 apitolisib 0 2 72	8	2.781	1.32	0.355	0.148	0.746	0.241	1.15	0.995	1.49e-07	NA	0.947	0.339	0.832	0.475	0.292	1.27	0.993	2.95e-07	NA
HCC1806	GDC-0980	1	72	sigmoid	sigmoid	HCC1806 apitolisib 0 1 72	8	2.696	1.24	0.339	0.152	0.739	0.223	1.15	0.995	1.52e-07	NA	0.947	0.339	0.832	0.475	0.292	1.27	0.993	2.95e-07	NA
HCC1806	GDC-0980	3	72	sigmoid	sigmoid	HCC1806 apitolisib 0 3 72	8	3.149	1.8	0.418	0.132	0.77	0.31	1.14	0.995	1.41e-07	NA	0.947	0.339	0.832	0.475	0.292	1.27	0.993	2.95e-07	NA
Hs 578T	AZD-6482	1		sigmoid	sigmoid	Hs578T AZD6482 1	8	2.041	2.04	0.401	0.177	18.5	-1.0	0.498	0.986	2.92e-06	NA	3.16	0.484	0.835	3.16	0.0	0.532	0.98	7.93e-06	NA
BT-20	Pictilisib	1	72	sigmoid	sigmoid	BT20 pictilisib 0 1 72	8	2.085	1.25	0.163	0.177	5.0	-1.0	0.791	0.994	1.75e-07	NA	1.52	0.323	0.838	1.52	0.0	0.865	0.989	1.22e-06	NA
BT-549	Buparlisib	2	72	sigmoid	sigmoid	BT549 buparlisib 0 2 72	8	1.913	0.681	-0.306	0.217	1.08	-0.538	1.59	0.998	1.31e-08	NA	0.821	0.132	0.838	0.769	0.0514	1.66	0.996	8.95e-08	NA
BT-549	MK2206	1	72	sigmoid	sigmoid	BT549 MK-2206 0 1 72	8	1.811	Inf	0.632	0.189	0.103	0.58	0.8	0.911	0.000695	NA	Inf	0.692	0.839	0.101	0.642	0.73	0.911	0.000717	NA
HCC38	PI103	1	72	sigmoid	sigmoid	HCC38 PI-103 0 1 72	8	1.782	0.755	0.222	0.201	0.601	0.12	1.2	0.996	4.45e-08	NA	1.39	0.416	0.839	0.494	0.359	1.23	0.995	1.01e-07	NA
Hs 578T	PIK-93	1		sigmoid	sigmoid	Hs578T PIK-93 1	8	2.033	1.44	0.276	0.175	8.38	-1.0	0.624	0.991	6.57e-07	NA	2.0	0.401	0.84	2.0	0.0	0.672	0.99	9.72e-07	NA
HCC70	TGX221	1	72	sigmoid	sigmoid	HCC70 TGX-221 0 1 72	8	1.381	0.539	0.344	0.244	0.245	0.278	1.03	0.986	2.58e-06	NA	Inf	0.578	0.84	0.229	0.536	1.02	0.986	2.87e-06	NA
Hs 578T	MK2206	1		sigmoid	sigmoid	Hs578T MK-2206 1	8	2.039	Inf	0.608	0.165	0.087	0.665	2.09	0.9	0.00101	NA	Inf	0.641	0.845	0.0803	0.689	1.9	0.908	0.000775	NA
BT-20	AZD-6482	1	72	sigmoid	sigmoid	BT20 AZD6482 0 1 72	8	2.043	1.34	0.182	0.173	3.83	-0.782	0.893	0.982	5.6e-06	NA	1.65	0.342	0.845	1.65	0.0	0.977	0.972	2.09e-05	NA
Hs 578T	Alpelisib	2		flat	flat	Hs578T alpelisib 2	8	2.513	Inf	0.668	0.131	0.0	0.668	0.01	0.599	0.0647	0.856	Inf	0.634	0.847	0.0	0.634	0.01	0.541	0.0969	0.833
Hs 578T	MK2206	2		sigmoid	sigmoid	Hs578T MK-2206 2	8	2.530	Inf	0.664	0.131	0.0699	0.752	1.34	0.75	0.0156	NA	Inf	0.628	0.848	0.0616	0.717	1.21	0.767	0.0126	NA

|<
<<
Previous
Page 10 of 18
Next
>>
>
226 to 250 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)